# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-08-2024 | 03-31-2024 | 10-Q | |
2 | 02-28-2024 | 12-31-2023 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
First Quarter Financial ResultsCash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $...
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin me...
Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and...
Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and...
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform and raises the price targe...
Full Year 2023 Financial ResultsCash Position: As of December 31, 2023, NewAmsterdam recorded cash of $340.5 million, compared ...